ME Therapeutics has taken a novel approach to cancer immunotherapy. Using our combined expertise in tumour immunology, T cell biology and myeloid cell development, we are developing biological and small molecule drugs to target novel pathways involved in cancer-induced immune suppression. Our therapies have the potential to work on their own and in combination with other cancer immunotherapies across several cancer types.